Clinical Trials Logo

Clinical Trial Summary

This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 and extension study one CTBM100C2303E1 (all visits), who were proven infected with Pseudomonas aeruginosa at enrollment into CTBM100C2303.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01069705
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date February 12, 2010
Completion date March 19, 2012

See also
  Status Clinical Trial Phase
Recruiting NCT04335383 - Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Not yet recruiting NCT06035055 - Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis Phase 4
Completed NCT00774072 - Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization Phase 2
Completed NCT00515229 - Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo Phase 2
Terminated NCT00333385 - Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Phase 4
Recruiting NCT03638830 - Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa Phase 2
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT00633191 - Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis Phase 1/Phase 2
Completed NCT00712166 - Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa Phase 3
Recruiting NCT04171817 - Animal-Assisted Visitation Program Chlorhexidine Trial Phase 4
Completed NCT02696902 - Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects Phase 2
Completed NCT01319253 - A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies N/A
Recruiting NCT05282082 - Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Recruiting NCT04803695 - Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT05632315 - PMT for MDRO Decolonization Phase 2
Completed NCT01055847 - Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection Phase 2
Completed NCT01745796 - Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)
Recruiting NCT04673175 - Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Recruiting NCT05616221 - Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection Phase 2